Intech Investment Management LLC Buys 3,980 Shares of Integer Holdings Co. (NYSE:ITGR)

Intech Investment Management LLC grew its stake in shares of Integer Holdings Co. (NYSE:ITGR) by 51.1% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 11,767 shares of the medical equipment provider’s stock after acquiring an additional 3,980 shares during the quarter. Intech Investment Management LLC’s holdings in Integer were worth $1,559,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Mather Group LLC. increased its holdings in Integer by 304.3% in the 4th quarter. Mather Group LLC. now owns 190 shares of the medical equipment provider’s stock worth $25,000 after buying an additional 143 shares in the last quarter. R Squared Ltd bought a new stake in Integer in the 4th quarter worth about $44,000. Versant Capital Management Inc increased its holdings in Integer by 98.4% in the 4th quarter. Versant Capital Management Inc now owns 369 shares of the medical equipment provider’s stock worth $49,000 after buying an additional 183 shares in the last quarter. Principal Securities Inc. increased its holdings in Integer by 31.2% in the 4th quarter. Principal Securities Inc. now owns 639 shares of the medical equipment provider’s stock worth $85,000 after buying an additional 152 shares in the last quarter. Finally, Contravisory Investment Management Inc. increased its holdings in Integer by 210.8% in the 4th quarter. Contravisory Investment Management Inc. now owns 693 shares of the medical equipment provider’s stock worth $92,000 after buying an additional 470 shares in the last quarter. 99.29% of the stock is currently owned by institutional investors.

Integer Stock Down 1.0 %

ITGR stock opened at $115.07 on Friday. Integer Holdings Co. has a twelve month low of $107.11 and a twelve month high of $146.36. The company has a quick ratio of 2.09, a current ratio of 2.95 and a debt-to-equity ratio of 0.62. The stock has a market cap of $3.87 billion, a P/E ratio of 34.25, a PEG ratio of 1.72 and a beta of 1.24. The business’s 50-day moving average price is $132.59 and its 200-day moving average price is $132.31.

Integer (NYSE:ITGR) last posted its quarterly earnings data on Thursday, February 20th. The medical equipment provider reported $1.43 earnings per share for the quarter, missing analysts’ consensus estimates of $1.46 by ($0.03). Integer had a net margin of 6.92% and a return on equity of 11.65%. The company had revenue of $449.50 million for the quarter, compared to analysts’ expectations of $446.28 million. On average, equities research analysts forecast that Integer Holdings Co. will post 6.01 EPS for the current year.

Wall Street Analysts Forecast Growth

Several equities research analysts recently commented on ITGR shares. KeyCorp lifted their price objective on Integer from $144.00 to $154.00 and gave the stock an “overweight” rating in a report on Friday, January 24th. Citigroup boosted their price target on Integer from $130.00 to $145.00 and gave the company a “neutral” rating in a research note on Wednesday, December 11th. Benchmark boosted their price target on Integer from $140.00 to $150.00 and gave the company a “buy” rating in a research note on Friday, February 21st. Truist Financial boosted their price target on Integer from $147.00 to $163.00 and gave the company a “buy” rating in a research note on Wednesday, December 11th. Finally, Oppenheimer downgraded Integer from an “outperform” rating to a “market perform” rating in a research note on Friday, February 21st. Two research analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $149.00.

Integer Company Profile

Integer Holdings Corporation operates as a medical device outsource manufacturer in the United States, Puerto Rico, Costa Rica, and internationally. It operates through two segments, Medical and Non-Medical. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, non-vascular, urology, and gastroenterology procedures.